Pharmalink, a specialty pharmaceutical company, has appointed of Renee Aguiar-Lucander as Chief Executive Officer.
Her appointment comes at a key time for the company, now that it has completed its highly successful NEFIGAN Phase 2b clinical trial with Nefecon in patients with IgA nephropathy at risk of end stage renal disease.
The Pharmalink team will pursue a range of initiatives, including raising private or public capital for the Phase 3 trial, expanding the company’s development platform, in-licensing of additional compounds as well as partnering.
Pharmalink’s current CEO, Johan Haggblad, will take on the role of COO and will continue to lead clinical and product development.
Prior to joining Pharmalink, Aguiar-Lucander was partner and COO of Omega Fund Management, an international healthcare fund based in Boston.
She was previously a partner at the venture group of 3i Group, where she managed the European and US legacy healthcare and technology portfolios, and had responsibility for the group’s public holdings.
Before this, Aguiar-Lucander was European Group Head and Managing Director at a US-based global investment bank.
She has more than 12 years of corporate finance experience, including merger and acquisitions, corporate restructurings and raising private and public capital for growth companies in Europe and the US.
She has held senior management positions in a technology growth company and has significant corporate board experience in both private and public companies. Aguiar-Lucander holds a BA in Finance from Stockholm School of Economics and a MBA from INSEAD.